Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Non-Invasive Imaging for Cording in Breast Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
Alphonse Taghian, MD, PhD, Massachusetts General Hospital Identifier:
First received: August 25, 2011
Last updated: June 30, 2014
Last verified: June 2014

August 25, 2011
June 30, 2014
August 2011
August 2012   (final data collection date for primary outcome measure)
The pathophysiology of cording following treatment for breast cancer [ Designated as safety issue: No ]
The cohort of 15 subject's images will be reviewed by the PI and a designated physician from the department of vascular medicine to determine if there is a vascular origin in the cords. Each image will be accessed for the following findings or involvement: Venous, lymphatic, fluid pockets, and striations on the cord.
Same as current
Complete list of historical versions of study NCT01427166 on Archive Site
Cording and the onset of breast cancer related lymphedema [ Designated as safety issue: No ]
Subjects will be measured every 4-7 months with a perometer to determine if breast cancer related lymphedema is present.
Same as current
Not Provided
Not Provided
Non-Invasive Imaging for Cording in Breast Cancer Patients
Evaluation of Non Invasive Imaging for Assessing the Pathophysiology of Cording in Patients Treated for Breast Cancer

To date, the scientific literature has yet to provide sufficient evidence regarding the pathophysiology of cording. The objective of this protocol is to evaluate the utility of non invasive vascular imaging for assessing the pathophysiology of cording in a small study cohort of patients who were treated for breast cancer. The hypothesis is that cording may have a vascular etiology

Cords are bands of tissue that are present in the axilla following breast cancer surgery and may extend across the antecubital fossa and into the forearm. Cords are often painful to patients and limit their shoulder range of motion.The proposed study design involves the recruitment of patients who are enrolled in Partners Protocol # 2008P000540, a prospective analysis of symptoms, functionality and quality of life questionnaire to evaluate lymphedema in patients following treatment for breast cancer. This protocol recruits newly diagnosed breast cancer patients prior to any treatment interventions. Subjects are required to undergo volumetric arm measurements and complete the Lymphedema Evaluation Following Treatment for Breast Cancer Questionnaire (LEFT-BC) which will allow for the evaluation of changes in functionality, upper extremity utilization (fear associated avoidance), and quality of life. Throughout treatment patients will be screened before and after each treatment event: surgery, chemotherapy and radiation. Following the conclusion of treatment for breast cancer, patients will be measured at least 2 times per year (every 4-7 months). If during these study visits the patient notes cording symptoms, the research staff administering the questionnaire will be alerted. At this point, they will notify a designated medical provider who will perform a physical examination of the area to confirm the presence of cording. Once the presence of cording is verified, the patient will be provided with the opportunity to enroll in the proposed trial. Due to the current limited knowledge on the nature of the condition, the patients arm and axilla will have to be imaged within 7 days of the physical exam confirmation. The patients will be asked to return to the vascular imaging lab located on the Massachusetts's General Hospital's main campus. They will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe.

Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
Breast Cancer
Other: Non invasive venous ultrasound
Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants must be enrolled in Partners protocol # 2008P000540 "Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer"
  • Confirmed case of cording by a medical provider (Physician, Nurse Practitioner, Physician Assistant)
  • Participants must be at least 18 years of age
  • Life expectancy of greater than 1 year.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Willingness to comply with required follow up Perometer measurements and clinical visits.

Exclusion Criteria:

  • Participants who are not enrolled or have been removed from Partners Protocol # 2008P000540 will be excluded from this trial.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of prior surgery or radiation to the head, neck, upper limb, or trunk.
  • Patients with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
10-279, R01CA139118
Alphonse Taghian, MD, PhD, Massachusetts General Hospital
Massachusetts General Hospital
National Cancer Institute (NCI)
Principal Investigator: Alphonse G Taghian, MD PhD Massachusetts General Hospital
Massachusetts General Hospital
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP